{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T18:06:07Z","timestamp":1774634767934,"version":"3.50.1"},"reference-count":17,"publisher":"Japanese Society of Internal Medicine","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,11,15]]},"DOI":"10.2169\/internalmedicine.5389-25","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T18:07:26Z","timestamp":1745863646000},"page":"3252-3256","source":"Crossref","is-referenced-by-count":1,"title":["Rare Case of Severe Pancreatitis Induced by Encorafenib and Cetuximab in BRAF V600E-Positive Colorectal Cancer"],"prefix":"10.2169","volume":"64","author":[{"given":"Yu","family":"Miyakawa","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Ishigaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobumi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisaki","family":"Suzumori","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tamada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gota","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoku","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"},{"name":"Department of Oncology and General Medicine, IMSUT Hospital, The Institute of Medicine Science, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117: 4623-4632, 2011.","DOI":"10.1002\/cncr.26086"},{"key":"2","unstructured":"2. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27: 1386-1422, 2016."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in <i>BRAF<\/i> V600E-mutated colorectal cancer. N Engl J Med 381: 1632-1643, 2019.","DOI":"10.1056\/NEJMoa1908075"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab as a new standard of care for previously treated <i>BRAF<\/i> V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol 39: 273-284, 2021.","DOI":"10.1200\/JCO.20.02088"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Taieb J, Lonardi S, Desai J, et al. Adverse events associated with encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer: an in-depth analysis of the BEACON CRC study. Clin Colorectal Cancer 22: 59-66, 2023.","DOI":"10.1016\/j.clcc.2022.12.003"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Takeda K, Yokoe M, Takada T, et al. Assessment of severity of acute pancreatitis according to new prognostic factors and CT grading. J Hepatobiliary Pancreat Sci 17: 37-44, 2010.","DOI":"10.1007\/s00534-009-0213-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kureyama Y, Hanaoka Y, Tomita D, Matoba S, Kurayanagi H. Pancreatitis after treatment with encorafenib, binimetinib, and cetuximab for BRAF V600E mutation-positive colorectal cancer. Cureus 16: e60188, 2024.","DOI":"10.7759\/cureus.60188"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 410: 37-40, 2001.","DOI":"10.1038\/35065000"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6: 322-327, 2005.","DOI":"10.1016\/S1470-2045(05)70168-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Irrera N, Bitto A, Interdonato M, Squadrito F, Altavilla D. Evidence for a role of mitogen-activated protein kinases in the treatment of experimental acute pancreatitis. World J Gastroenterol 20: 16535-16543, 2014.","DOI":"10.3748\/wjg.v20.i44.16535"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ogliari FR, Rodolfo Masera GL, Gueli R, Chini C. Dabrafenib and trametinib induced pancreatitis: a case report and review of the literature. Anticancer Drugs 32: 215-217, 2021.","DOI":"10.1097\/CAD.0000000000001009"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of <i>BRAF<\/i>-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2: 227-235, 2012.","DOI":"10.1158\/2159-8290.CD-11-0341"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10: 559-568, 2009.","DOI":"10.1016\/S1470-2045(09)70112-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Thornton E, Howard SA, Jagannathan J, et al. Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients. Br J Radiol 85: 1420-1426, 2012.","DOI":"10.1259\/bjr\/19815818"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Shinagare AB, Howard SA, Krajewski KM, Zukotynski KA, Jagannathan JP, Ramaiya NH. Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management. AJR Am J Roentgenol 199: 1259-1265, 2012.","DOI":"10.2214\/AJR.12.8782"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Tabernero J, Velez L, Trevino TL, et al. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with <i>BRAF<\/i> V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ESMO Open 6: 100328, 2021.","DOI":"10.1016\/j.esmoop.2021.100328"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ismael H, Horst M, Farooq M, Jordan J, Patton JH, Rubinfeld IS. Adverse effects of preoperative steroid use on surgical outcomes. Am J Surg 201: 305-309, 2011.","DOI":"10.1016\/j.amjsurg.2010.09.018"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/22\/64_5389-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T03:27:31Z","timestamp":1763177251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/22\/64_5389-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":17,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5389-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]},"article-number":"5389-25"}}